To contain spreading of the Coronavirus SARS CoV-2 and avoid endangerment of public health, the National Center for Tumor Diseases (NCT) Heidelberg cancels this year’s NCT run. Nevertheless, the organizers would like to use the 26th of June to still express the spirit of this year’s NCT run “NCT-RUNning against cancer”, especially during these times.
Since 2012, the NCT charity run “NCT-RUNing against cancer” is a fixed date for many. Everyone has their own motivation to participate. The meeting of more than 5.500 runners has always been a great sign of community: for health, for the fight against cancer, for those affected and for cancer research at NCT Heidelberg.
Due to the spreading of the newly discovered Coronavirus SARS CoV-2 and necessary measures nothing remains as it was. “As consequences for the following months are hardly predictable at present, we have to react in time. With great regret, we decided to cancel this year's NCT run”, says Stefan Fröhling, Managing Director of NCT Heidelberg and Head of the Division of “Translational Medical Oncology” at German Cancer Research Center (DKFZ).
Participants registered already will be contacted within the next few days and informed about the reimbursement of already paid entry fees. Alternatively, participants can donate their entry fees to the benefit of NCT Heidelberg.
"Next to the possibility to donate the entry fees in support of NCT Heidelberg, we are working on a collective initiative for June 26th, which will enable everyone to set an individual sign and still express the spirit of the NCT run – NCT-RUNning against Cancer – despite the cancellation of the run”, says Dirk Jäger, Managing Director of NCT Heidelberg and Medical Director of Medical Oncology at Heidelberg University Hospital (UKHD). NCT Heidelberg will inform about available options in a few weeks.
Contact:
Regina Hohmann, Tel.: 06221 56-36146
regina.hohmann@nct-heidelberg.de
Andreas Klein, Tel.: 06221 56-35762
andreas.klein@nct-heidelberg.de
Further information: www.nct-lauf.de
Images for the press release are available free of charge on the internet:
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/Meldungen/Bilder/Laufschuhe.jpg
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/Meldungen/Bilder/810_9987.jpg
Notice for image material in press releases:
The use of images is free of charge. The NCT Heidelberg permits one-time use in connection with coverage of the subject of the press release. Please list the photo credits: “NCT Heidelberg”. The transmission of photographic material to third parties is only permitted after prior consultation with the NCT Press Office (Tel. 06221 56 5930, Email: friederike.fellenberg@nct-heidelberg.de). Use for commercial purposes is prohibited.
Press contact:
Dr. Friederike Fellenberg
National Center for Tumor Diseases Heidelberg (NCT)
Press and Public Relations
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 56-5930
Fax: +49 6221 56-5350
Email: friederike.fellenberg@nct-heidelberg.de
www.nct-heidelberg.de
Doris Rübsam-Brodkorb
Heidelberg University Hospital and Medical Faculty of the University of Heidelberg
Press and Public Relation
Im Neuenheimer Feld 672
69120 Heidelberg
Tel.: +49 6221 56-5052
Fax: +49 6221 56-4544
Email: doris.ruebsam-brodkorb@med.uni-heidelberg.de
Dr. Sibylle Kohlstädt
German Cancer Research Center (DKFZ)
Communications and Marketing
Im Neuenheimer Feld 280
69120 Heidelberg
Tel.: +49 6221 42-2843
Fax: +49 6221 42-2968
Email: s.kohlstaedt@dkfz.de
www.dkfz.de
National Center for Tumor Diseases Heidelberg (NCT)
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital (UKHD) and German Cancer Aid. The NCT’s goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. This is true for both diagnosis and treatment, follow-up care or prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here, the patients benefit from an individual treatment plan prepared in interdisciplinary expert rounds, so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, the NCT Heidelberg has maintained a partner site in Dresden. The Hopp Children’s Cancer Center (KiTZ) was established in Heidelberg in 2017. The pediatric oncologists at KiTZ work together in parallel structures with the NCT Heidelberg.
Heidelberg University Hospital (UKHD)
Heidelberg University Hospital (UKHD) is one of the most important medical centers in Germany; Heidelberg University’s Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 13,000 individuals and are involved in training and qualification. Every year approximately 65,000 patients are treated as inpatients and 56,000 as day patients in more than 50 specialized clinical departments with around 2,000 beds, with more than 1 million patients being treated as outpatients. Together with the German Cancer Research Center and German Cancer Aid, the Heidelberg University Hospital established The National Center for Tumor Diseases (NCT) Heidelberg as the leading oncology center of excellence in Germany. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present 3,700 aspiring physicians and doctors are studying in Heidelberg.
German Cancer Research Center (DKFZ)
The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.
The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Together with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic.
In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.